Friday, July 10, 2026

pharma · Prurigo Nodularis · Vitiligo

Incyte

Incyte clinical programs — 10 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

1801 Augustine Cut-Off, Wilmington, Delaware 19803, US HQ
3,381 Employees
NMPA registrant Type
Company details
Status
Public
HQ
1801 Augustine Cut-Off, Wilmington, Delaware 19803, US
Employees
3,381
Programs
53
Drugs
61
Patents
0
Intelligence · Clinical Programs

Incyte projects

10 ClinicalTrials.gov programs sponsored by Incyte.

Incyte has 10 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. INCA 33989-101

    Incyte

    Myeloproliferative Neoplasms

    phase 1 other active

    1 trial
  2. INCA33890

    Incyte

    Solid Tumors

    phase 1 small molecule active

    1 trial
  3. INCB 123667-101

    Incyte

    Advanced or metastatic solid tumors

    phase 1 other active

    1 trial
  4. INCB 161734-101

    Incyte

    Advanced or metastatic solid tumors

    phase 1 other active

    1 trial
  5. INCB 57643-103

    Incyte

    Treatment of participants with MF, MDS, ET, or MDS/MPN

    phase 1 other active

    1 trial
  6. INCB 81776-101

    Incyte

    Advanced malignancies.

    phase 1 other active

    1 trial
  7. INCB 99280-205

    Incyte

    Solid tumor

    phase 1 small molecule active

    1 trial
  8. INCB099280

    Incyte

    Advanced Solid Tumor

    phase 1 small molecule completed

    1 trial
  9. INCB160058-101

    Incyte

    Myeloproliferative Neoplasms

    phase 1 other active

    1 trial
  10. Itacitinib

    Incyte

    Acute Graft-versus-host Disease

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Incyte have?

10 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.